Cryosite Posts 28% EBITDA Growth With Major Facility Expansions Underway

Financial Performance Accelerates on Growing Clinical Demand

Cryosite Limited (ASX:CTE) has reported a strong financial run for the ten months ending 30 April 2026, with revenue climbing 22% to $13.8 million and EBITDA surging 28% to $3.4 million compared to the prior corresponding period. The company also improved its EBITDA margin by one percentage point to 25%, reflecting operational leverage as demand for its specialised clinical trial logistics services intensifies.

Underlying growth is broad-based, driven by increasing utilisation of existing infrastructure and a rising client base in the Ultra-Frozen (-80°C) and Cryogenic (-196°C) segments. These areas are benefiting from expanding global activity in biologics, cell and gene therapies, and mRNA-based medicines, which require stringent temperature controls. Cryosite’s April 2026 EBITDA performance marked a record month, signalling sustained momentum into May.

The company’s financial results build on its earlier half-year progress, where it reported a 22% revenue boost and warehouse expansion, positioning Cryosite for continued growth in clinical trial logistics.

Capacity Expansion Doubles Primary Cool Room Space

Operationally, Cryosite has completed a major expansion of its primary 2°C to 8°C cool room at its Ferndell Street facility, more than doubling capacity. This project was delivered on time, under budget, and fully funded through operating cash flows. Quality validation is underway, with full commissioning expected imminently, enabling Cryosite to accommodate the growing volume of clinical trial samples requiring controlled storage.

Meanwhile, the commissioning of the Adderley Street freehold warehouse in Auburn; acquired in November 2025 for $9.5 million; is progressing on schedule and budget. This new facility adds approximately 2,100 square metres of storage space, effectively doubling Cryosite’s overall capacity and providing critical dual-site resilience. Initial client discussions are focusing on new market segments, which could diversify revenue streams further. The warehouse deal itself was previously noted as a key strategic milestone that doubled storage capacity in Sydney freehold warehouse acquisition.

Balance Sheet Strengthened With NAB Refinancing

Cryosite has also bolstered its financial footing by refinancing its debt facility with the National Australia Bank. The new four-year facility extends maturity to 2030, providing long-term certainty and flexibility. The company has already repaid about $1 million of principal, reducing the outstanding balance to roughly $5.6 million. This refinancing reflects NAB’s confidence in Cryosite’s growth strategy and financial position.

Supported by strong operating cash flows, Cryosite’s debt reduction aligns with its communicated strategy, and the company carries no other debt obligations. Additionally, Cryosite lodged its first Research & Development Tax Incentive claim during the period, signalling ongoing investment in innovation.

Leadership and Operational Resilience Amid Global Pressures

On the people front, Cryosite has strengthened its leadership team with the appointment of Paul Cohen to head Regulatory Affairs and Quality Assurance, bringing decades of pharmaceutical and medical device experience. Interim General Manager Gavan Corke is stepping up during Dr Alicia Steel’s maternity leave, maintaining operational momentum.

Despite global supply chain and cost pressures linked to geopolitical tensions, Cryosite has mitigated impacts through favourable supplier contracts, including fixed fuel surcharges that have shielded clients from rising costs. The company’s sustainability credentials remain strong, earning an EcoVadis Gold Medal for responsible business practices in FY26.

Infrastructure Growth and Client Pipeline Point to Sustained Expansion

As Cryosite moves into the final months of FY26, it is poised to capitalise on its expanded infrastructure, record storage revenues, and a growing pipeline of domestic and international clients. The commissioning of both the Ferndell Street cool room expansion and the Adderley Street warehouse will be critical to supporting this growth trajectory.

With the global life sciences sector continuing to invest heavily in temperature-controlled logistics, Cryosite’s unique capabilities and expanded footprint position it well to capture long-term opportunities. The company’s progress builds on its earlier storage capacity doubling and revenue surge, underscoring a clear growth narrative.